Trusted Resource for Clinical Trials, Protocols & Progress
ADME stands for Absorption, Distribution, Metabolism, and Excretion—a core set of pharmacokinetic processes that describe what the body does to a drug. Understanding these parameters is essential before any new drug can be tested in humans. ADME studies form the bridge between drug discovery and early clinical development, helping researchers predict how a drug will behave in the human body.
Click to read the full article.
The quality of a preclinical study depends heavily on its design. A well-structured study can offer reliable, reproducible, and regulatory-acceptable data that supports the transition of a drug into human trials. Poorly designed studies, on the other hand, can lead to inconclusive results, ethical concerns, and wasted resources.
Click to read the full article.
The journey of a new medical intervention is meticulously mapped through various clinical trial phases. These stages are designed to answer critical questions related to a drug’s pharmacology, therapeutic effect, dosage requirements, and long-term safety. A clear understanding of these phases is fundamental for anyone involved in pharmaceutical research and development.
Click to read the full article.
Translational science refers to the process of turning laboratory discoveries and preclinical findings into therapeutic interventions that can be tested and used in humans. It forms the critical bridge between basic science and clinical application, ensuring that the right questions are asked, and the right data is generated to inform early-phase human trials.
Click to read the full article.
Animal studies are essential for evaluating the safety and efficacy of new drugs before human trials. However, their use comes with significant ethical responsibility. Animals are sentient beings, and using them in research must be justified with a clear scientific need, minimal suffering, and adherence to humane practices. Ethics in animal testing ensures that scientific advancement never comes at the cost of unnecessary animal suffering.
Click to read the full article.
Following promising Phase II results, investigational therapies advance to Phase III trials to validate their effectiveness and continue comprehensive safety evaluations. These large, often global studies are critical for generating the high-quality clinical data required by regulatory agencies like the FDA, EMA, and CDSCO for market authorization. Successful Phase III trials are often the final hurdle before commercialization.
Click to read the full article.
Good Laboratory Practice (GLP) is a quality system concerned with the organizational processes and conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported. It ensures the reliability and integrity of data generated for regulatory submissions across global agencies.
Click to read the full article.
Phase 0 trials, also known as microdosing studies, are the earliest phase of human clinical research. Introduced as part of an exploratory IND (Investigational New Drug) framework by the U.S. FDA, Phase 0 studies are designed to collect preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data in humans using very low doses of investigational drugs.
Click to read the full article.
A microdosing study involves the administration of extremely low, sub-therapeutic doses of a drug to human subjects to evaluate early pharmacokinetic (PK) and pharmacodynamic (PD) behavior. These studies fall under the category of Phase 0 clinical trials and are designed to provide rapid, human-specific data with minimal risk.
Click to read the full article.
Not every drug candidate is suitable for a Phase 0 microdosing study. These trials are designed to generate early pharmacokinetic (PK) and pharmacodynamic (PD) data without therapeutic intent. Therefore, selecting the right candidates is essential to ensure that the limited scope of Phase 0 delivers meaningful and predictive insights.
Click to read the full article.
